Menu
Back to Journals » Biologics: Targets and Therapy » Volume 3
Ustekinumab in the therapy of chronic plaque psoriasis
Authors O’Neill JL, Kalb R
Published 25 March 2009 Volume 2009:3 Pages 159—168
DOI https://doi.org/10.2147/BTT.S3498
Review by Single anonymous peer review
Peer reviewer comments 2
Jenna L O’Neill, Robert E Kalb
State University of New York at Buffalo, School of Medicine and Biomedical Sciences, Department of Dermatology, NY, USA
Abstract: Psoriasis is a chronic inflammatory disorder characterized by T cell dysregulation and a chronic inflammatory infiltrate within the epidermis. Several cytokines play an important role in the pathogenesis of psoriasis, including interleukin-12 (IL-12) and IL-23. These cytokines act via induction of pro-inflammatory cytokines which promote chronic inflammation and auto-reactivity. Ustekinumab is a fully human monoclonal antibody against the common p40 subunit of IL-12 and IL-23. Two randomized, double-blind, placebo-controlled trials of ustekinumab have demonstrated significant and prolonged efficacy in the treatment of plaque psoriasis. Adverse events were generally similar across treatment and control groups. Studies are ongoing to assess the long term safety and efficacy profiles of ustekinumab.
Keywords: ustekinumab, psoriasis, plaque
© 2009 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.